Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NE3W
|
|||
| Former ID |
DNCL001601
|
|||
| Drug Name |
GTx-024
|
|||
| Synonyms |
(R)-Ostarine; 1132656-73-5; (2R)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide; C19H14F3N3O3; 841205-47-8 pound not1202044-20-9; SCHEMBL2197534; CHEBI:94527; DTXSID70649384; BCPP000135; AOB87717; ZINC35793633; BCP9001038; NCGC00408913-01; AS-17044; FT-0673314; Y0247; 370C134; I06-2154; BRD-K16621777-001-01-9; (R)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Muscle atrophy [ICD-11: FB32.Y; ICD-9: 728.2] | Phase 3 | [1] | |
| Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [2] | ||
| Company |
GTx
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H14F3N3O3
|
|||
| Canonical SMILES |
CC(COC1=CC=C(C=C1)C#N)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
|
|||
| InChI |
1S/C19H14F3N3O3/c1-18(27,11-28-15-6-2-12(9-23)3-7-15)17(26)25-14-5-4-13(10-24)16(8-14)19(20,21)22/h2-8,27H,11H2,1H3,(H,25,26)/t18-/m0/s1
|
|||
| InChIKey |
JNGVJMBLXIUVRD-SFHVURJKSA-N
|
|||
| CAS Number |
CAS 841205-47-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01355497) Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.